A small bacterial protein called R1R2 reduced fibrosis-promoting cells’ ability to go from the blood, where they normally reside, to lung tissue, a mouse study shows. The research, “R1R2 peptide ameliorates pulmonary fibrosis in mice through fibrocyte migration and differentiation,” was published in the journal PLOs One. Scientists…
News
Pulmonary rehabilitation programs can significantly improve exercise ability, breathing, and overall quality of life in patients with pulmonary diseases, including idiopathic pulmonary fibrosis (IPF), and should be considered as “a first line therapy” for these people, researchers report. Indeed, the study “Effectiveness of pulmonary rehabilitation in patients with…
Long-term use of Boehringer Ingelheim’s Ofev (nintedanib) prevents disease progression in patients with idiopathic pulmonary fibrosis (IPF), according to the latest results of the TOMORROW trial and its open-label extension. The study, “Long-term treatment of patients with idiopathic pulmonary…
A protein called RUNX2 contributes to lung tissue scarring, which makes it a good target for the development of a pulmonary fibrosis treatment, a study reported. It does this differently in two types of lung cells, suggesting that scientists might need to develop therapies that targeted each of the cell types,…
A small RNA molecule, called microRNA 101, prevents the proliferation and activation of fibroblasts, thereby eliminating pulmonary fibrosis (PF) in mice, researchers at Oklahoma State University (OSU) have found. Their study, “MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation,” appeared in the Journal of Biological…
A new class of class of compounds called trihydroxyphenolics inhibits TGF-beta 1, the key driver in specific cells of lung fibrosis, researchers found, suggesting the compounds may be a potential therapeutic approach to reduce the effects of fibrosis. The study, “Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and…
The Pulmonary Fibrosis Foundation’s inaugural PFF Walk raised more than $234,000, three times the goal of $70,000, for research on the disease and for patient services. More than 1,000 patients, families, caregivers and healthcare professionals from 40 U.S. states participated in the event Sept. 9 to mark Pulmonary…
Autoimmunity may drive idiopathic pulmonary fibrosis (IPF), according to a study that found a link between certain autoantibodies —those that target the body’s own cells and tissues — and disease progression in these patients. The study, “Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic…
Patients with idiopathic pulmonary fibrosis (IPF) are prone to depression and anxiety, which clearly affects their quality of life — regardless of age, gender or disease’s severity as measured in pulmonary function tests, researchers in Korea report. The scientists also suggest that these people may benefit from cognitive behavioral therapy…
The Pulmonary Fibrosis Foundation (PFF) has announced its keynote speakers for the upcoming PFF Summit 2017, a biennial meeting set for Nov. 9-11 in Nashville, Tennessee. During the event, physicians and researchers will present their most current work on pulmonary fibrosis (PF), stem cell therapies, medical tourism and advances in…
